BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Taragarestrant readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Taragarestrant\, from ClinicalTrials.gov 
 estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06954961-9088@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Taragarestrant: Phase 3 readout est. (NCT06954961)
DESCRIPTION:Taragarestrant\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Adva
 nced or Metastatic Breast Cancer\nEstimated primary completion: 30 Novembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/taragarestran
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 954961
URL:https://assetmemo.bio/drug/taragarestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07336771-9088@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taragarestrant: Phase 1/2 readout est. (NCT07336771)
DESCRIPTION:Taragarestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer
 .\nStudy: JSKN016 in Combination With D-0502 for Locally Advanced or Metas
 tatic HR-Positive\, HER2-Negative Breast Cancer\nEstimated primary complet
 ion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 aragarestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07336771
URL:https://assetmemo.bio/drug/taragarestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
